The utility of quality of life (QOL) as an evaluative tool in clinical psychiatric research and drug trials could be enhanced by developing appropriate conceptual models of QOL, specific for psychiatric disorders.
In our proposed model, QOL of individuals maintained on antipsychotic drug therapy for schizophrenia, is viewed as the subject's perception of the outcome of an interaction between severity of psychotic symptoms, side-effects including subjective responses to antipsychotic drugs, and the level of psychosocial performance.
In order to test the validy of the model in clinical setting, we selected a sample of 62 schizophrenic patients clinically stabilized on antipsychotic drug therapy, and measured their subjective QOL and other potentially relevant clinical and psychosocial factors.
Standardized scales including the positive and negative syndromes scale (PANSS), abnormal involuntary movements scale (AIMS), Hillside Akathisia scale (HAI), and the social performance schedule (SPS) were used for this purpose.
Results of a multiple regression analysis using subjective quality of life as the outcome variable, indicated that severity of schizophrenic symptoms (partial R²=0.32, p<0.0001) and subjective distress caused by akathisia (partial R²=0.11, p<0.01) and neuroleptic dysphoria (partial R²=0.06, p<0.05), accounted for nearly half of the variance, while the contribution from the psychosocial indicators was negligible....
Mots-clés Pascal : Schizophrénie, Evaluation, Méthodologie, Qualité vie
Mots-clés Pascal anglais : Schizophrenia, Evaluation, Methodology, Quality of life
Notice produite par :
ORS Auvergne - Observatoire Régional de la Santé d'Auvergne
Code Inist : 002B30A11. Création : 16/10/1997.